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Abstract 
Conserved epitopes are targets commonly researched to be part of universal vaccine candidates against influenza 
viruses (IV). These conserved epitopes need to be cross‑protecting against distinct IV subtypes and to have a strong 
immunogenic potential. Nevertheless, subunit vaccines generally require a strong adjuvant to enhance their immu‑
nological effects. Herewith, we compare four different adjuvants differing in their immunological signatures that 
may enhance efficacy of a conserved hemagglutinin (HA)‑epitope from IV, the NG‑34, to define the most efficient 
combination of antigen/adjuvant to combat IV infections. Soluble NG‑34 was mixed with adjuvants like aluminium 
hydroxide (AH) and AddaVax, known to induce Th2 and humoral responses; CAF01 which displays a biased Th1/Th17 
profile and Diluvac Forte which augments the humoral response. Combinations were tested in different groups of 
mice which were subjected to immunological analyses. CAF01 + NG‑34 induced a complete immune response with 
the highest IgG1, IgG2c titers and percentages of activated CD4 T cell promoting IFN‑γ, IL‑2 and TNF‑α producing cells. 
Furthermore, in NG‑34 stimulated mice splenocytes, cytokine levels of IFN‑γ, IL‑1β, IL‑6, IL‑10, IL‑17 and TNF‑α were 
also the highest in the CAF01 + NG‑34 mouse group. This complete induced immune response covering the humoral 
and the cellular arms of the adaptive immunity promoted by CAF01 + NG‑34 group suggests that CAF01 could be a 
good candidate as an adjuvant to combine with NG‑34 for an efficacious vaccine against IV. However, more studies 
performed in IV hosts as well as studies with a challenge model are further required.
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Introduction
Purified antigens, mostly identified using in silico tools, 
are the constituants of subunit vaccines. These types of 
vaccines own numerous advantages when compared with 
the conventional inactivated-type vaccines, for instance: 
higher purity, greater safety (no need for special handling 
of infectious viruses) and a quicker massive production. 
Nevertheless, soluble antigens are often poorly immu-
nogenic and require an adjuvant when the antigen is 
delivered [1]. This aspect makes the pursuit of a proper 
adjuvant important when developing subunit vaccines. 
The present study takes into account this aspect and 
combines an influenza virus hemagglutinin antigen (a 
conserved HA1-epitope NG-34) with four distinct adju-
vants known to trigger different immune responses in 
order to determine the optimal antigen/adjuvant combi-
nation that may function effectively against IV.
Adjuvants are defined as substances whose main func-
tion is to enhance the ability of the vaccine to induce an 
appropriate immune response in the absence of adverse 
effects. Their mechanisms of adjuvanticity can be catego-
rized accordingly to the criteria of O’Hagan and Valiante 
[2], which classifies them depending on their delivery 
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system and their immunopotentiation. However, few 
adjuvants are currently licensed [3–5] and a long delay 
exists in licensing new types. This is creating inconven-
ience for novel emerging vaccines, mainly since they can-
not utilize novel adjuvants focused on exploring novel 
strategies, such as generating also robust cell-mediated 
immune (CMI) responses [6–8].
The seasonal updated Trivalent/Quadrivalent Inacti-
vated Vaccine (TIV/QIV) commercially available against 
influenza viruses (IV), covers up to 90% of human vac-
cines worldwide [9]. Lamentably, immune responses 
induced are strain-specific and do not cope with possi-
ble mutations or probable new emerging strains caused 
by antigenic shift. For decades, the idea of developing a 
universal vaccine which provides a broad-spectrum pro-
tection against a variety of IV has been pursued. In order 
to achieve this challenge, inducing antibodies by immu-
nizing with conserved regions of the viral proteins has 
been investigated. Nonetheless, these epitope-based vac-
cines usually confer short-lived protection and are com-
promised compared to current licensed vaccines [10]. In 
the present experimental study, we evaluated a suitable 
adjuvant candidate (novel and registered) immunologi-
cally to be mixed with a well-studied HA-epitope by our 
group [11], the NG-34. The study pursued a prototype for 
a universal vaccine, thus the murine model was used in 
preliminary research.
NG-34 peptide, predicted by Informational Spectrum 
Methodology (ISM) [12, 13], is located within the site 
E in the N terminus of HA1 [14], in a domain close to 
the receptor binding site (RBS) of the HA, character-
ized for being relatively conserved. Its role in inducing 
specific antibodies as well as CD4 T cells in the pig 
model has been documented. Recently, it has been 
shown that NG-34 was effective as a pig influenza vac-
cine in combating against a  heterologous challenge by 
reducing shedding and inducing neutralizing antibod-
ies against a SwH3N2 virus [11]. In poultry, another 
study supported its cross-protective effect against an 
H7 HPAIV strain [15].
The four adjuvants tested (Alhydrogel 2.0%, 
AddaVax™, cationic adjuvant formulation 01 (CAF01) 
and Diluvac  Forte®) were selected in view of their 
dissimilar immunological profiles and mechanisms 
of adjuvanticity (O’Hagan and Valiante [2]) summa-
rized in Table  1. Among them, Alhydrogel 2.0% and 
AddaVax™ (similar to  MF59®) are formulated in human 
registered vaccines while CAF01 is in clinical develop-
ment stages [16]. Diluvac  Forte®, however, is applied 
only in veterinary studies and has been widely utilized 
in swine protein vaccines [17, 18]. However, knowing 
that pigs are also natural influenza hosts and regard-
ing its safety and its easy mass-vaccination delivery, we 
decided to include Diluvac  Forte® as a suitable porcine 
influenza adjuvant candidate.
Significant differences in the induction of humoral 
as well as cellular immune responses were only 
observed when combinations of AH + NG-34 and 
CAF01 + NG-34 were used. However, a combination 
of CAF01 + NG-34 was also effective in upregulating 
a wide array of cytokines as well as IgG2c antibodies, 
representing the most complete immune response. 
Nonetheless, further studies in influenza hosts are vital 
to evaluate the efficacy and effectiveness of the vaccine 
combination in natural IV infections.
Table 1 Characteristics of each of the four adjuvants employed
TH = T helper; Nalp3 = NACHT, LRR and PYD domains‑containing protein 3; APC = antigen presenting cells.
Adjuvant name Adjuvant type/
chemical constituents
Immunological profile Mechanism of action 
(delivery system/
immunopotentiation)
Stage of development References
Alhydrogel® referred 
as AH
Aluminum salts (Mineral 
salts)/Aluminum 
hydroxide
TH2, humoral Depot effect, delayed 
clearance/Activate 
Nalp3 inflammasome
Both human and veteri‑
nary licensed vaccines
[47–51]
AddaVax™ (Invivogen); 
similar to  MF59®
Oil‑in‑water emulsion/
Squalene and poly‑
sorbate mixture
TH2, humoral Enhance antigen pres‑
entation/Induce APC 
maturation
Licensed European 
seasonal influenza 
vaccines
[52–57]
CAF01 Particulate: Cationic lipo‑
some/Dimethyldiocta‑
decylamonium (DDA) 
and α,α′‑trehalose‑6,6′‑
dibehenate (TDB)
TH1,  TH17, humoral Protect antigen from 
destruction/Induce 
APC maturation
Phase 1 [8, 19, 34, 58, 59]
Diluvac Forte™ Oil‑in‑water emulsion/α‑
tocopherol
Humoral Enhance antigen pres‑
entation/Induce APC 
maturation
Approved in Animal 
Health
[17, 18, 60, 61]
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Materials and methods
Mice handling and experimental design
Mouse experiments took place at Statens Serum Institut 
(SSI) animal facilities. For this adjuvant testing research 
study, a total of twenty-seven 7–8 week old female mice 
of the inbred strain C57BL/6 (Envigo, Huntingdon, UK) 
were employed. Upon arrival, all mice were allowed to 
rest for 1 week previous to the first immunization. More-
over, they were randomly distributed into six separate 
cages according to the number of groups required in the 
experiment (groups A to F). Animals were provided food 
and water ad libitum.
Six groups (group A to F) of n = 5 (in exception of 
group A, n = 3 and group B, n = 4) were immunized twice 
subcutaneously (s.c) at the base of the tail with a 21-day 
intervals. In group A, mice were not immunized (control 
group). In the rest of the groups (groups B to F), a dose 
of 15  µg/animal of conserved HA-epitope NG-34 was 
injected alone (group B) or adjuvanted with AH (group 
C), AddaVax (group D), CAF01 (group E) or Diluvac 
Forte (group F) (Table  2). Three  weeks after the second 
immunization, all animals were euthanized.
Sampling from each individual of the study was per-
formed 3 weeks after the second immunization, at day 
42 (termination day) when blood, spleens and inguinal 
lymph nodes were collected.
Adjuvants and vaccine preparation
CAF01, Diluvac  Forte® (Statens Serum Institut, Copen-
hagen, Denmark), AddaVax™ (Invivogen, Toulouse, 
France) and aluminium hydroxide (Al(OH)3, Alhydrogel 
2.0%) (Croda Biosector, Frederikssund, Denmark) were 
the adjuvants employed.
Mouse vaccines with an end volume of 200 µL were 
prepared by mixing the antigen (15 µg/animal/dose) dis-
solved in Tris-buffer with 9% (w/v) trehalose, in a ratio 
of 1:1 with the adjuvant except for Alhydrogel 2.0% (each 
vaccine comprised 500  µg aluminum content/200  µL) 
[19, 20] and group A which was not immunized.
CAF01 was freshly prepared in agreement with other 
studies and comprised: 250  µg/50  µg dimethyldiocta-
decylammonium (DDA)/trehalose 6,6  V-dibehenate 
(TDB)/100 µL [8, 19].
Cells, antigens and viruses
Madin-Darby Canine Kidney (MDCK, ATCC CCL-
34) cells were used in the seroneutralization assays. 
They were properly cultured in Dulbecco’s Modified 
Eagle Medium (DMEM) supplemented with 10% fetal 
bovine serum (FBS), 1% penicillin/streptomycin and 1% 
l-glutamine.
NG-34 epitope predicted by ISM was synthesized by 
GL Biochem Ltd, Shanghai, China. Its sequence cor-
responds with 34 amino acids in the HA1 region from 
the strain A/Catalonia/63/2009 (pH1N1) [GenBank 
ACS36215] [11].
Purified HA from A/California/04/09(H1N1)pdm09 
and from A/Aichi/2/1968(H3N2) were purchased from 
Sino Biological, Beijing, China (cat. no. 40340-V08B and 
11707-V08H, respectively).
SwH1N1 (A/swine/Spain/003/2010 H1N1 IV) [Gen-
Bank JQ319725 and JQ319727] and SwH3N2 (A/swine/
Spain/003/2010 H3N2 IV) [GenBank JQ319724 and 
JQ319726] were the viruses used.
Organ preparation
Spleens and lymph nodes were treated as follows: they 
were forced through a 70  μM filter nylon mesh (BD Bio-
sciences, San Jose, CA, USA), suspended in Roswell Park 
Memorial Institute (RPMI) media without FBS and fur-
ther centrifuged for 5  min at 1800  rpm. At that point, 
cells were resuspended in 1  mL using complete RPMI 
(cRPMI) (supplemented with HEPES, penicillin–strep-
tomycin, sodium pyruvate, l-glutamine and non-essen-
tial amino acids) with 10% FBS (v/v). Finally, all samples 
were counted using NucleoCassetes (ChemoMetec A/S, 
AllerØd, Denmark) on the  NucleoCounter® NC-100™ 
(reagents and materials from ChemoMetec A/S, AllerØd, 
Denmark).
Immunoassays in mice for antigen‑specific serum 
antibodies
Maxisorb Plates (Nunc) were coated with 2 µg/well of 
either NG-34 epitope or HA: A/California/04/09 (H1) 
in buffer carbonate bicarbonate pH = 9.6 and left to 
incubate overnight at 4 °C. The next day, the plates were 
blocked during 1  h 30  min at room temperature (RT) 
using 2% BSA  PBS solution. Mouse sera were analyzed 
in threefold dilution series in PBS with 1% BSA, start-
ing with a 30-fold dilution. After a 2-hour incubating 
period at RT and three washes with 0.2%Tween20 PBS 
buffer, HRP-conjugated secondary antibodies (rabbit 
Table 2 Representation of  the  six mice groups (Groups 
A-F)
n= number of mice; s.c = subcutaneously.
Group n Antigen Adjuvant Inoculation 
route
A 3 – – –
B 4 NG‑34 – s.c.
C 5 NG‑34 Alhydrogel 2.0% s.c.
D 5 NG‑34 AddaVax™ s.c.
E 5 NG‑34 CAF01 s.c.
F 5 NG‑34 Diluvac  Forte® s.c.
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anti-mouse IgG1; Southern Biotech, Birmingham, AL, 
USA; and IgG2c; Invitrogen, San Diego, CA, USA) were 
added with 1%BSA PBS at dilutions: 1:20 000 (IgG1) or 
1:5000 (IgG2c) and incubated during 1 h at RT. Reitera-
tively, the plates were washed and developed using 3, 3′, 
5, 5′-tetramethylbenzidine (TMB) substrate (Kem-En-
Tec Diagnostics, Kuldyssen, Denmark). The reaction was 
later stopped by adding 0.2 M  H2SO4 and the plates were 
read using a two-step fully automated ELISA (Hamiltion 
Starlet System, Switzerland) at 450–620 nm wavelength.
Intra‑cellular flow cytometry staining for mice splenocytes 
stimulated in vitro with NG‑34 antigen
In splenocytes, the production of cytokines IFN-γ, TNF-
α, IL-2 and IL-17 was assessed in the T cell population. 
For that purpose, cells were stained similarly as described 
in [21] but with few modifications. Briefly, splenocytes 
 (106 cells/well) were stimulated with 2 µg/mL of NG-34 
peptide during 1  h at 37  °C and subsequently, incu-
bated 6 h at 37 °C with brefeldin A (2.5 µg/mL) in order 
to block cytokine production. After this period, cells 
remained O/N at 4  °C. Additionally, from each group 
two pools were differentially made: not stimulated (nega-
tive control) or stimulated with PMA/ionomycin (posi-
tive control). Next day, all cells were stained utilizing the 
antibodies: CD4-BV786 (BD Pharmingen, San Diego, 
CA, USA; 56331), CD44-FITC (eBioscience, Frankfurt, 
Germany; 11-0441), CD8-PerCpCy5.5 (eBioscience, 
45-0081). The cells were then permeabilized using fix/
perm (BD) and washed in permeabilization wash (BD). 
Subsequently, the cells were stained with IL-2-APC-
Cy7 (BD Pharmingen, 560547), TNF-α-PE (eBioscience, 
12-7321), IFN-γ-PE-Cy7 (eBioscience, 25-7311) and IL-
17a-APC (eBioscience, 17-7177). The cells were acquired 
on a FACS Fortessa instrument using DIVA software (BD 
Bioscience, USA) and all the data analyzed using FlowJo 
software (Tree Star Inc.). Upon their acquisition, the cells 
were gated following this pattern: live > singlets > lym-
phocytes > CD3 + > CD4 + versus CD8 + . Furthermore, 
cytokine-producing cells (IFN-γ, IL-2, IL-17 and TNF-α) 
within the CD4 + CD44 high population were measured. 
Compensation beads (BD Pharmingen, USA) were used 
to compensate the fluorophores.
Flow cytometry staining in mice for cells in the inguinal 
lymph nodes
Cells from the inguinal lymph nodes were collected from 
all individuals; the cells were plated  (106 cells/well) and 
treated with Mouse BD Fc Block™ (BD Pharmingen, 
553142) to block non-antigen-specific bindings of immu-
nogloblulins to Fcγ III and Fcγ II receptors. Two panels 
of antibodies were used to stain cell populations in the 
germinal centers (GC) of the lymph nodes; GC B cells 
 (B220+  IgD−  CD38−  GL7+) and T follicular helper cells 
(TFH)  (B220−  CD4+ PD-1+  CXCR5+). The following 
antibodies were mixed in PBS 1% FBS: GL7-FITC (BioLe-
gend GmbH, Koblenz, Germany; 144604), IgG1-PE (BD 
Pharmingen, 550083), B220-PerCP-Cy5.5 (BD Pharmin-
gen, 552771), CD38-PE-CY7 (eBioscience, 25-0381) and 
IgD-BV786 (BD Pharmingen, 563618) to stain the B cells 
in the GC. To stain the TFH cell population, the follow-
ing antibody panel was used: CD4-FITC (BD Pharmin-
gen, 553047); CD279(PD1)-PE (BD Pharmingen, 551892); 
CD45R(B220)-PerCP-Cy5.5 (eBioscience, 65-0865-14), 
CXCR5-BV421 (BD Pharmingen, 562889) and live/dead-
EF780 (BD Pharmingen, 562889). After an incubation 
period of 30 min at 4  °C, the cells were acquired on the 
FACS LSRII instrument using DIVA software (BD Bio-
science, USA) and all the acquired data analyzed using 
FlowJo software (Tree Star Inc.). Compensation beads 
(BD Pharmingen, USA) were used to compensate the 
fluorophores.
Mouse cytokine assay
Splenocytes were seeded (2 × 105/well) and stimulated 
with the NG-34 epitope (5  µg/mL); media cRPMI (as 
negative control) and concavalin A (1  µg/mL) (as posi-
tive control) (GE Healthcare, Marlborough, MA, USA). 
The supernatants were harvested after 72  h incubation 
at 37 °C and a 9-plex panel MSD standard Th1/Th2/Th17 
which checks IFN-γ, TNF-α, IL- 5, IL-10, IL-13 and IL-17 
cytokines together with two U-plex panels for IL-6 and 
IL-1β detection were ran following the manufacturer’s 
instructions (MSD, Rockville, MD, USA).
Hemagglutination inhibition (HI) assay and serum 
neutralization test (SNT)
Specific hemagglutination inhibition (HI) titers in mice 
sera were determined as the reciprocal of the later dilu-
tion of sera that inhibited hemagglutination. The protocol 
was adjusted to the recommendations provided by the 
World Organization for Animal Health (OIE) [22]. Sam-
ples from each group were pooled and ran in duplicates. 
A positive and negative reference serum (GD Animal 
Health, Deventer, The Netherlands) were also included in 
the assays to validate the technique.
Specific seroneutralizing antibody titers were evalu-
ated. First, samples from each mice group were pooled, 
heat inactivated (56  °C for 30  min), diluted two-fold 
with DMEM (supplemented with 1% penicillin/strep-
tomycin and 1% l-glutamine) and incubated for 2  h 
at 37  °C with 100  TCID50/well with the SwH1N1 (A/
swine/Spain/003/2010 H1N1 IV) and SwH3N2 (A/
swine/Spain/003/2010 H3N2 IV) previously treated with 
porcine-trypsin (Sigma-Aldrich, St. Louis, MO, USA). 
Later on, the mixture of sera-virus was transferred into 
Page 5 of 11Sisteré‑Oró et al. Vet Res           (2020) 51:57  
pre-washed plates with confluent MDCK cells and kept 
at 37 °C with 5%  CO2. After 7 days, the cytopathic effect 
(CPE) was read and the titers were expressed as the 
reciprocal dilution of serum that neutralized 100  TCID50 
of the challenged strain in 50% of the cultured replicates. 
Furthermore, in each plate there were added media con-
trols (no virus), virus controls (no serum) and positive 
and negative reference sera from GD Animal Health, The 
Netherlands.
Statistical analysis
For statistical analysis, Prism 6 software (GraphPad v6.01, 
San Diego, CA, USA) was used. One-way ANOVA or a 
non-parametric test (Friedman test) followed by Dunnett 
multiple comparisons test was performed (assigning as 
control group: group B, the non-adjuvanted group). Sta-
tistically significant differences detected are illustrated by 
asterisks in each figure and explained in the correspond-
ing figure legends.
Results
Specific humoral immune responses after 2nd vaccination
IgG1 and IgG2c antibody responses were analyzed 
against the NG-34 epitope and against the complete 
HA from A/California/04/09 (H1N1) (Figure  1). NG34-
specific IgG1 titers were higher in AH + NG-34 and 
CAF01 + NG-34 groups, displaying statistically signifi-
cant differences (P < 0.05) when compared with the non-
adjuvanted group (Figure  1A). Regarding NG34-specific 
IgG2 titers, the CAF01 + NG-34 mice group achieved the 
highest titers with statistically major significant differ-
ences (P < 0.0001) when compared to the non-adjuvanted 
group (Figure  1B). The rest of the adjuvanted groups 
(AH + NG-34, Addavax + NG-34, Diluvac Forte + NG34) 
were barely inducing IgG2c titers. Furthermore, HA1-
specfic IgG1 and IgG2c titers were also in concordance 
with the NG-34 specific antibody titers (Figures 1C and 
D). The AH + NG-34 group elicited high HA1-specific 
antibody levels (P < 0.05) but only the CAF01 + NG34 
group achieved significant statistical differences for both 
Figure 1 Specific humoral responses elicited after immunizations with different adjuvant‑NG34 combinations. Serum samples 
from individual mice from groups A–F were collected after second immunization and analyzed in serial dilutions for IgG1 and IgG2c titers. A 
NG34‑specfic IgG1 and B IgG2c antibody titers and HA1‑specific C IgG1 and D IgG2c antibody titers. Adjuvanted groups were compared to group 
B (the non‑adjuvanted group) using a non‑parametric test (Friedman test) followed by Dunnett’s post‑test. *P < 0.05; **P < 0.01, *** P < 0.001, 
****P < 0.0001.
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of the IgG1 (P < 0.001) and IgG2 (P < 0.01) antibody titers 
against the non-adjuvanted group (P < 0.01).
Specific cellular immune responses in the spleen
NG-34 antigen-specific cellular response was meas-
ured in the spleen. Intracellular CD4 and/or CD8 
specific cytokines produced upon NG-34 stimula-
tion was analyzed by flow cytometry. While in all the 
groups CD4 T cell response was observed, the CD8 T 
cell response was merely present. In parallel, percent-
ages of CD4 + CD44high T cells in NG34-stimulated 
spleens were also determined. The AH + NG-34 and 
CAF01 + NG-34 groups showed the highest percentages 
(P < 0.05) in comparison to group B (Figure 2A). Only the 
CAF01 + NG-34 mice group demonstrated significant 
differences in intracellular cytokine, IFN-γ (P < 0.001), 
IL-2 (P < 0.05) and TNF-α (P < 0.01) produced by NG-34 
stimulated spleens (Figures  2B–D). Additionally, IL-17 
producing cells were the highest in the CAF01 + NG-34 
group although no statistical differences were observed 
among different adjuvant/NG-34 combinations 
(Figure 2E).
Supernatants of NG34-stimulated spleens harvested 
after 72 h were analyzed with a multiplex system for dif-
ferent cytokines like IFN-γ, TNF-α, IL-5, IL-10, IL-13 
and IL-17 (Th1/Th2/Th17 type). Similarly, IL-6 and IL-1β 
levels were also evaluated (Figure 3). Statistically signifi-
cant differences in IFN-γ (P < 0.001), TNF-α (P < 0.01), 
IL-10 (P < 0.001), IL-17 (P < 0.001), IL-6 (P < 0.01) and 
IL-1β (P < 0.001) cytokine release were only detected 
in the CAF01 + NG-34 group when compared to the 
non-adjuvanted group (Figures  3A, B, D, F–H). IL-5 
in the AH + NG-34 group (Figure  3C) and IL-13 in the 
CAF01 + NG-34 group (Figure 3E) were detected at low 
concentrations although no statistically significant differ-
ences were observed in IL-5 and IL-13 among the groups.
Alteration in the inguinal lymph node cell population 
in immunized mice
Differences in the number of cells present in the GC of 
lymph nodes were detected. Significantly higher per-
centages of B cells (P < 0.005) were observed in the 
CAF01 + NG-34 group (Figure  4A). In contrast, no sta-
tistical differences were observed in TFH cells, although 
Figure 2 Cellular responses in the spleens of immunized mice. NG34‑stimulated spleen cells from individual mice (groups A–F) were collected 
and analyzed for cytokine production by flow cytometry. Percentages of A CD4 + CD44high, B CD4 + CD44high IFN‑γ, C CD4 + CD44high IL‑2, D 
CD4 + CD44high TNF‑α and E CD4 + CD44high IL‑17 (2) are represented.
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in CAF01 + NG34 and Diluvac Forte + NG-34 groups an 
increase in TFH was noticed (Figure 4B).
Obtained HI and SNT titers in mouse sera
HI titers were negative in all mice sera for each of the 
tested IV. SNT titers were either negative or low (1:10) 
in CAF01 + NG-34 and Diluvac Forte + NG-34 groups 
against SwH1N1 virus. Against SwH3N2 virus, both 
groups (CAF01 + NG-34 and Diluvac Forte + NG-34) 
achieved a 1:40 titer (Table 3).
Discussion
Many immunogens/subunit antigens do not show strong 
immunogenicity, making the use of adjuvants necessary 
to reinforce their immune effect. In the present study, 
we focused on selecting the most suitable adjuvant that 
could better aid immunogenically when administered in 
combination with the NG-34 conserved HA-epitope.
Various groups of mice were either not immunized or 
immunized with NG-34 epitope alone or combined with 
adjuvants: AH, AddaVax, CAF01 and Diluvac  Forte®. 
Figure 3 Cellular responses in the supernatants of NG‑34 stimulated spleens of immunized mice. Harvested supernatants of NG34 
stimulated spleens from individual mice from groups A‑F were collected to determine the levels of A IFN‑γ, B TNF‑α, C IL‑5, D IL‑10, E IL‑13, F IL‑17, 
G IL‑6 and H IL‑1β. Adjuvanted groups were compared to group B (the non‑adjuvanted group) using Ordinary One‑way ANOVA test followed by 
Dunnett’s post‑test. *P < 0.05; **P < 0.01, ***P < 0.001, ****P < 0.0001.
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Interestingly, mice vaccinated with CAF01 + NG-34 elic-
ited specific humoral and cellular immune responses to 
the conserved NG-34 HA-epitope (Figures  1 and 2), a 
dual immune induction widely considered ideal for an IV 
vaccine.
The AH + NG-34 group induced a polarized Th2-type 
response leading to significantly higher NG34-specific 
IgG1 titers (Figures  1A and 2A), and CAF01 combined 
with NG-34, promoted the highest levels of IgG1 (Fig-
ure 1A). The CAF01-NG-34 group also induced an IgG2c 
response, being the only peptide/adjuvant combination 
capable of inducing such a response (Figure  1B) which 
is in line with other studies published using other anti-
gens and CAF01 [8, 20]. These induced IgG2a/c titers 
are regarded as an important component for IV vaccines 
since they mediate protection when virus neutralizing 
titers are absent [23, 24].
Strong HI titers were not induced by any of the 
evaluated epitope/adjuvant combinations. Only 
CAF01 + NG-34 and Diluvac Forte + NG-34 groups dis-
played SNT titers albeit at low levels (Table  3). These 
results did not correlate with the high HI titers induced 
when using MF59 adjuvant in IV vaccines [25, 26]. Per-
haps, MF59-like adjuvants (Addavax) function bet-
ter when the complete HA or IV strain are included 
in the vaccine formulation [27, 28]. Furthermore, the 
Addavax + NG-34 group did not boost Th1 and Th2 as 
demonstrated in other studies [25, 26]. In contrast, our 
results were concordant with results using CAF01 com-
bined with TIV, which conferred protection in an IHA-
independent manner [29].
To achieve cross-protection between heterolo-
gous strains, an appropriate T-cell response seems 
to be necessary [30]. In this work, the highest cel-
lular responses were exhibited by the AH + NG-34 
and CAF01 + NG-34 groups (Figure  2A). The results 
obtained in the AH + NG-34 partly correlated with 
the trend for a predominant Th2 differentiation and 
Th2-type cytokine profile, usually promoted by alu-
minum salts [31, 32]. Statistically significant increase 
in CD4 CD44high population and highest IFN- γ, 
IL-2 and TNF-α responses (Th1-type cytokines) were 
observed in mice from CAF01 + NG34 (Figures  2A 
and C) as also reported in other studies [6, 19, 33, 
34]. Significantly higher titers of IFN-γ, TNF-α, IL-10, 
IL-17, IL-6 and IL-1β were also observed in the NG34-
stimulated spleen cell supernatants obtained from the 
CAF01 + NG-34 vaccinated animals (Figures 3A, B, D, 
F–H). These results could be associated with the role 
of CAF01 in inducing Th1-cytokines and also with the 
property of one of the CAF01 compounds (the TDB) 
which leads to the secretion of IL-1β, IL-6 and TNF-α 
[35]. Furthermore, the rise in IL-17 levels of the mice 
from CAF01 + NG-34 (Figure  3F) could be related to 
the Th17 response that CAF01 promotes through the 
TLR-independent Syk/Card9-dependent pathway [36] 
(Figure 2). Other cytokines not from a Th1/Th17 profile 
were also boosted (IL-10 and IL-6) by CAF01 + NG-34 
Figure 4 Changes in inguinal lymph node population. Lymph nodes samples from individual mice (groups A‑F) were collected and analyzed by 
flow cytometry A the percentage of B cells in the GC (B) the percentage of TFH. Adjuvanted groups were compared to the non‑adjuvanted group 
using Ordinary One‑way ANOVA test followed by Dunnett’s post‑test. *P < 0.05; **P < 0.01, ***P < 0.001, ****P < 0.0001.
Table 3 SNT titers obtained from  the  six mice groups 
(groups A-F) against SwH1N1 and SwH3N2 isolates
SNT = serum neutralization test.
Group Adjuvant SNT titers
Against SwH1N1 Against 
SwH3N2
A – – –
B – – –
C Alhydrogel 2.0% – –
D AddaVax™ – –
E CAF01 1:10 1:10
F Diluvac  Forte® 1:40 1:40
Page 9 of 11Sisteré‑Oró et al. Vet Res           (2020) 51:57  
vaccinated mice (Figures  3D and G). IL-10 induction 
could be related to the CD4 TFH cells which might pro-
mote B cell proliferation, survival, and differentiation 
into antibody-secreting plasma cells [37–42].
The mice immunized with CAF01 + NG-34 displayed 
the greatest percentages of B cells population in the GC in 
the draining lymph nodes (Figure 4A). Other studies have 
reported CAF01 as an enhancer of GC reaction in com-
parison to other adjuvants such as AddaVax, aluminum 
hydroxide and CpG ODN 1826 [43] and recognized 
that this reaction is primordial for generating plasma 
and memory B cells [44]. In terms of the percentage of 
TFH, the highest percentage mean was achieved by the 
Diluvac Forte + NG-34 but followed immediately by the 
CAF01 + NG-34 group (Figure 4B). Although not statis-
tically significant, these data are of great relevance since 
the TFH cells promote long-lasting humoral immunity 
arising from the GC. CAF01 has been reported to have 
a more than a year duration inducing CMI responses due 
to its DDA compound which forms a depot at the injec-
tion site [45].
The TDB component of CAF01 is essential for the 
induction of CMI responses and that it is recognized 
via the C-type lectin receptor MINCLE (CLEC4E). It 
is important to note that there may be species-specific 
differences in recognition and activation of this MIN-
CLE receptor. It is well known that CAF01 is a promis-
ing adjuvant in humans, inducing both antibody and 
CMI responses [16, 34] and also that CAF01 combined 
with Chlamydia trachomatis fusion proteins (Hirep1 and 
CTH93) induce strong CMI responses in Göttingen min-
ipigs [46]. Nevertheless, whether TDB is also an effec-
tive immunostimulator in poultry remains to be assessed 
and further studies are therefore required to develop the 
CAF01 + NG-34 as a vaccine for poultry.
As a first step, this study may provide insights into what 
may be occurring when administering CAF01 + NG-34 
to influenza hosts (such as pig and poultry). With regards 
to the released umbrella of cytokines as well as antibod-
ies induced, CAF01 ought to be a potential adjuvant to be 
mixed with the conserved NG-34 epitope.
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